Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 2/20 | 0.32 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911103 | 0.85 | MRGPRX1 (0.32) | MRGPRX1HSD17B1HSD17B2TP53TDP1 | |
| SCHEMBL4804688 | 0.74 | MRGPRX1 (0.36) | MRGPRX1 | |
| SCHEMBL4802500 | 0.68 | ALDH1A1 (0.40) | MRGPRX1 | |
| SCHEMBL5513895 | 0.66 | PIM1 (0.50) | HSD17B1HSD17B2PIM1HTR1ATDP1 | |
| SCHEMBL24917553 | 0.66 | TSHR (0.34) | — | |
| SCHEMBL4803381 | 0.65 | HSD17B10 (0.34) | HSD17B1HSD17B2TDP1CA3CA6 | |
| SCHEMBL288465 | 0.64 | ACHE (0.39) | MRGPRX1 | |
| SCHEMBL28481670 | 0.64 | TRPA1 (0.41) | HSD17B1HSD17B2TDP1CA6 | |
| SCHEMBL6127812 | 0.63 | KDM4E (0.33) | — | |
| SCHEMBL14111367 | 0.63 | EPHB4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7410996-B2 | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-08-03 | — | — | US | disclosed |
| US-7037932-B2 | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1397129-B1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1587782-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | Eli Lilly and Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1587781-A1 | 3-ARYLOXY/THIO-2,3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004043903-A1 | 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043904-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1397129-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094262-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ADRB3, HTR3C, CHRNB3 | F2RL1 2713/4885MRGPRX1 1003/4885HSD17B1 518/4885 |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ADRB3, SLC6A3, SLC6A2 | F2RL1 3090/4885MRGPRX1 1509/4885HSD17B1 1150/4885 |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ADRA2C, ADRB1, TPH1 | F2RL1 4213/4885MRGPRX1 1089/4885HSD17B1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.